Featured Content
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options. Learners will also get a look ahead at emerging therapeutic strategies and clinical trials...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Myeloma News
Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Antithrombotic Treatment Resistance in Multiple Myeloma Likely Multifactorial
Source: Myeloma - Hematology Advisor Researchers sought to determine the factors involved in the resistance to antithrombotic therapy that is observed among patients with multiple myeloma. Read More
Osteocyte CIITA aggravates osteolytic bone lesions in myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Triplet Maintenance After HSCT Improves PFS vs Lenalidomide Alone in Multiple Myeloma
Source: Myeloma - Hematology Advisor Post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone (KRd) improves outcomes, when compared with lenalidomide alone, in patients with multiple myeloma (MM), according to research presented at the EHA 2022...
Dara-KRD Induction Effective in High-Risk, Newly Diagnosed Myeloma
Source: Myeloma - Hematology Advisor Among some patients with transplant-eligible, newly diagnosed multiple myeloma (MM), a daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRD) induction regimen is both safe and yields deep responses prior to...
Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model
Source: Myeloma : nature.com subject feeds Post Content Read More
Factors Related to Adherence to Oral Multiple Myeloma Therapy
Source: Myeloma - Hematology Advisor Lack of adherence to cancer treatment using oral therapies can contribute to poor treatment outcomes, and a team of researchers conducted a study to investigate factors that may be related to lack of adherence to oral agents....
Post-Transplant Carfilzomib, Lenalidomide, and Dexamethasone May Be New Standard of Care in Multiple Myeloma
Source: Myeloma - Hematology Advisor Minimal residual disease (MRD)/risk-adapted post-transplant carfilzomib, lenalidomide, and dexamethasone (KRd) therapy demonstrated superior progression-free survival (PFS) compared with lenalidomide (R) maintenance therapy in...
IKEMA Update Reveals “Unprecedented” PFS in Relapsed Multiple Myeloma
Source: Myeloma - Hematology Advisor New data support isatuximab plus carfilzomib and dexamethasone (Isa-Kd) as standard care for relapsed multiple myeloma (MM), according to researchers. Updated data from the IKEMA trial showed that adding Isa to Kd significantly...
Recent Publications
Abnormal Metaphase Cytogenetics Predicts Venous Thromboembolism in Myeloma: Derivation and Validation of the PRISM Score
Blood. 2022 Jun 30:blood.2022015727. doi: 10.1182/blood.2022015727. Online ahead of print. ABSTRACT While venous thromboembolism (VTE) is an important treatment and disease-related complication in myeloma, a validated risk-prediction model including disease-specific...
Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure!
J Clin Oncol. 2022 Jun 30:JCO2200622. doi: 10.1200/JCO.22.00622. Online ahead of print. NO ABSTRACT PMID:35772041 | DOI:10.1200/JCO.22.00622
Response and Survival Estimates of Patients With Plasma Cell Myeloma in a Resource-Constrained Setting Using Protocols From High-Income Countries: A Single-Center Experience From Sri Lanka
JCO Glob Oncol. 2022 Jun;8:e2100352. doi: 10.1200/GO.21.00352. ABSTRACT PURPOSE: There is a significant disparity in global cancer care and outcome between countries. Progress in the treatment of symptomatic plasma cell myeloma (PCM) in high-income countries is not...
Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
Adv Ther. 2022 Jun 30. doi: 10.1007/s12325-022-02195-1. Online ahead of print. ABSTRACT INTRODUCTION: The combination of lenalidomide, bortezomib, and dexamethasone (RVd) has become standard of care for transplant-eligible patients with newly diagnosed MM (NDMM). This...
What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma
Target Oncol. 2022 Jun 30. doi: 10.1007/s11523-022-00897-8. Online ahead of print. ABSTRACT Immunomodulatory drugs (IMiDs) have become an integral part of therapy for both newly diagnosed and relapsed/refractory multiple myeloma (RRMM). IMiDs bind to cereblon, leading...
Highjacking myeloma’s niche with beefed-up CAR-Ts
Blood. 2022 Jun 30;139(26):3671-3672. doi: 10.1182/blood.2022015707. NO ABSTRACT PMID:35771562 | DOI:10.1182/blood.2022015707
Analysis of Coagulation Abnormality in Patients with Multiple Myeloma and Its Clinical Significance
Evid Based Complement Alternat Med. 2022 Jun 20;2022:5120967. doi: 10.1155/2022/5120967. eCollection 2022. ABSTRACT OBJECTIVE: To analyze the abnormal changes of coagulation indexes in patients with multiple myeloma (MM) and their clinical significance on prognosis....
Simultaneous Presentation of Multiple Myeloma and Lung Cancer: Case Report and Gene Bioinformatics Analysis
Front Oncol. 2022 Jun 13;12:859735. doi: 10.3389/fonc.2022.859735. eCollection 2022. ABSTRACT Patients diagnosed with more than one cancer generally develop the individual tumors sequentially. There are a few cases of co-occurring multiple myeloma and lung cancer...
